The burden of severe depression: A review of diagnostic challenges and treatment alternatives

Journal of Psychiatric Research

Volumn 41, Issue 3-4, 2007, Pages 189-206

  Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Electroconvulsive therapy; Selective serotonin reuptake inhibitor; Serotonin norepinephrine reuptake inhibitor; Severe depression; Transcranial magnetic stimulation; Tricyclic antidepressant; Vagus nerve stimulation

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; BIPOLAR II DISORDER; BRAIN DEPTH STIMULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONVULSION; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FATIGUE; HEART RATE VARIABILITY; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; NERVE STIMULATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT PROLONGATION; REMISSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; VERTIGO; XEROSTOMIA;

COMPLEMENTARY THERAPIES; COST OF ILLNESS; DEPRESSION; HUMANS;

EID: 33845220058     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2006.05.008     Document Type: Review

References (158)

1. Altshuler L.L., Bauer M., Frye M.A., Gitlin M.J., Mintz J., Szuba M.P., et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry 158 (2001) 1617-1622
2. Amsterdam J.D. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. Journal of Psychopharmacology 12 (1998) S99-S111
3. Ananth J. Treatment-resistant depression. Psychotherapy and Psychosomatics 67 (1998) 61-70
4. Anderson I.M. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 7 Suppl. 1 (1998) 11-17
5. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58 (2000) 19-36
6. Angst J., Amrein R., and Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. Journal of Clinical Psychopharmacology 15 (1995) 16S-23S
7. Appelberg B.G., Syvalahti E.K., Koskinen T.E., Mehtonen O.P., Muhonen T.T., and Naukkarinen H.H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Journal of Clinical Psychiatry 62 (2001) 448-452
8. Appelhof B.C., Brouwer J.P., van Dyck R., Fliers E., Hoogendijk W.J., Huyser J., et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. Journal of Clinical Endocrinology and Metabolism 89 (2004) 6271-6276
9. Barbee J.G., Conrad E.J., and Jamhour N.J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 65 (2004) 975-981
10. Beasley Jr. C.M., Holman S.L., and Potvin J.H. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Annals of Clinical Psychiatry 5 (1993) 199-207
11. Benkert O., Grunder G., Wetzel H., and Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research 30 (1996) 441-451
12. Benkert O., Szegedi A., and Kohnen R. Mirtazapine compared with paroxetine in major depression. Journal of Clinical Psychiatry 61 (2000) 656-663
13. Benkert O., Muller M., and Szegedi A. An overview of the clinical efficacy of mirtazapine. Human Psychopharmacology 17 Suppl. 1 (2002) S23-S26
14. Ben-Menachem E., Manon-Espaillat R., Ristanovic R., Wilder B.J., Stefan H., Mirza W., et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia 35 (1994) 616-626
15. Bhatia S.C., and Bhatia S.K. Major depression: selecting safe and effective treatment. American Family Physician 55 (1997) 1683-1698
16. Blythe D., and Hackett L.P. Cardiovascular and neurological toxicity of venlafaxine. Human and Experiment Toxicology 18 (1999) 309-313
17. Bohning D.E., Shastri A., Wassermann E.M., Ziemann U., Lorberbaum J.P., Nahas Z., et al. BOLD-f MRI response to single-pulse transcranial magnetic stimulation (TMS). Journal of Magnetic Resonance Imaging 11 (2000) 569-574
18. Bowden C.L., Schatzberg A.F., Rosenbaum A., Contreras S.A., Samson J.A., Dessain E., et al. Fluoxetine and desipramine in major depressive disorder. Journal of Clinical Psychopharmacology 13 (1993) 305-311
19. Boyce P., and Judd F. The place for the tricyclic antidepressants in the treatment of depression. Australia and New Zealand Journal of Psychiatry 33 (1999) 323-327
20. Braconnier A., Le Coent R., and Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. Journal of American Academy Child and Adolescent Psychiatry 42 (2003) 22-29
21. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Human Psychopharmacology 19 Suppl. 1 (2004) S21-S25
22. Broquet K.E. Status of treatment of depression. Southern Medical Journal 92 (1999) 846-856
23. Bruijn J.A., Moleman P., Mulder P.G., and van den Broek W.W. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Journal of Clinical Psychiatry 59 (1998) 657-663
24. Buckley N.A., and McManus P.R. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Bmj 325 (2002) 1332-1333
25. Burke W.J. Selective versus multi-transmitter antidepressants: are two mechanisms better than one?. Journal of Clinical Psychiatry 65 Suppl. 4 (2004) 37-45
26. Cappiello A., McDougle C.J., Delgado P.L., Malison R.T., Jatlow P., Charney D.S., et al. Lithium and desipramine versus desipramine alone in the treatment of severe major depression: a preliminary study. International Journal of Clinical Psychopharmacology 13 (1998) 191-198
27. Catafau A.M., Perez V., Gironell A., Martin J.C., Kulisevsky J., Estorch M., et al. SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. Psychiatry Research 106 (2001) 151-160
28. Cheeta S., Schifano F., Oyefeso A., Webb L., and Ghodse A.H. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. British Journal of Psychiatry 184 (2004) 41-47
29. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) 1986;90:131-138.
30. Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. International Journal of Clinical Psychopharmacology 16 (2001) 145-151
31. Clerc G.E., Ruimy P., and Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. International Journal of Clinical Psychopharmacology 9 (1994) 139-143
32. Conca A., Swoboda E., Konig P., Koppi S., Beraus W., Kunz A., et al. Clinical impacts of single transcranial magnetic stimulation (sTMS) as an add-on therapy in severely depressed patients under SSRI treatment. Human Psychopharmacology 15 (2000) 429-438
33. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry 59 (1998) 352-357
34. Craighead W.E., and Nemeroff C.B. The impact of early trauma on response to psychotherapy. Clinical Neuroscience Research 4 (2005) 405-411
35. Da Prada M., Zurcher G., Wuthrich I., and Haefely W.E. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neural Transmission Supplement 26 (1988) 31-56
36. Davidson J.R., Watkins L., Owens M.J., Dube E., Krolewicz S., Connor K.M., et al. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. Journal of Clinical Psychopharmacology 25 (2005) 480-484
37. De Montigny C., Grunberg F., Mayer A., and Deschenes J.P. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. British Journal of Psychiatry 138 (1981) 252-256
38. De Montigny C., Cournoyer G., and Morissette R. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Archives of General Psychiatry 40 (1983) 1327-1334
39. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., Demitrack M.A., and Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology 14 (2004) 457-470
40. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000a.
41. Dunbar G.C., Cohn J.B., Fabre L.F., Feighner J.P., Fieve R.R., Mendels J., et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. British Journal of Psychiatry 159 (1991) 394-398
42. Dunlop B.W., and Ninan P. Considerations in the pharmacologic management of severe depression. Medscape Psychiatry & Mental Health 8 (2003). Available from: www.medscape.com/viewarticle/462603
43. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361:799-808.
44. Fabre L.F., Brodie H.K., Garver D., and Zung W.W. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. Journal of Clinical Psychiatry 44 (1983) 88-94
45. Fava M. Weight gain and antidepressants. Journal of Clinical Psychiatry 61 Suppl. 11 (2000) 37-41
46. Feiger A.D., Flament M.F., Boyer P., and Gillespie J.A. Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. International Journal of Clinical Psychopharmacology 18 (2003) 203-210
47. Fisher S., Bryant S.G., and Kent T.A. Postmarketing surveillance by patient self-monitoring: trazodone versus fluoxetine. Journal of Clinical Psychopharmacology 13 (1993) 235-242
48. Flament M.F., Lane R.M., Zhu R., and Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. International Journal of Clinical Psychopharmacology 14 (1999) 259-275
49. Goldberg J.F., Burdick K.E., and Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry 161 (2004) 564-566
50. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., and Demitrack M.A. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology 24 (2004) 389-399
51. Goodnick P.J., Rush A.J., George M.S., Marangell L.B., and Sackeim H.A. Vagus nerve stimulation in depression. Expert Opinion on Pharmacotherapy 2 (2001) 1061-1063
52. Gorman J.M. Mirtazapine: clinical overview. Journal of Clinical Psychiatry 60 Suppl. 17 (1999) 9-13
53. Gorman J.M., Korotzer A., and Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrum 7 (2002) 40-44
54. Greenberg B.D., and Rezai A.R. Mechanisms and the current state of deep brain stimulation in neuropsychiatry. CNS Spectrum 8 (2003) 522-526
55. Grunhaus L., Dannon P.N., Schreiber S., Dolberg O.H., Amiaz R., Ziv R., et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biological Psychiatry 47 (2000) 314-324
56. Guelfi J.D., White C., and Magni G. A randomized double-blind comparison of venlafaxine and placebo in inpatients with major depression and melancholia. [Abstract]. Clinical Neuropharmacology 15 (1992) 323B
57. Guelfi J.D., White C., Hackett D., Guichoux J.Y., and Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry 56 (1995) 450-458
58. Guelfi J.D., Ansseau M., Corruble E., Samuelian J.C., Tonelli I., Tournoux A., et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International Journal of Clinical Psychopharmacology 13 (1998) 121-128
59. Guelfi J.D., Ansseau M., Timmerman L., and Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. Journal of Clinical Psychopharmacology 21 (2001) 425-431
60. Gutierrez M.A., Stimmel G.L., and Aiso J.Y. Venlafaxine: a 2003 update. Clincal Therapy 25 (2003) 2138-2154
61. Hamilton M. A rating scale for depression. Journal of Neurology and Neurosurgery in Psychiatry 23 (1960) 56-62
62. Handforth A., DeGiorgio C.M., Schachter S.C., Uthman B.M., Naritoku D.K., Tecoma E.S., et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 51 (1998) 48-55
63. Hausmann A., Kemmler G., Walpoth M., Mechtcheriakov S., Kramer-Reinstadler K., Lechner T., et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single centre, randomised, double blind, sham controlled "add on" trial. Journal of Neurology and Neurosurgery in Psychiatry 75 (2004) 320-322
64. Hawley C.J., Quick S.J., Harding M.J., Pattinson H., and Sivakumaran T. A preliminary study to examine the adequacy of long-term treatment of depression and the extent of recovery in general practice. British Journal of General Practice 47 (1997) 233-234
65. Henry J.A., Alexander C.A., and Sener E.K. Relative mortality from overdose of antidepressants. Bmj 310 (1995) 221-224
66. Hirschfeld R.M. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Journal of Clinical Psychiatry 60 (1999) 326-335
67. Janicak P.G., Dowd S.M., Martis B., Alam D., Beedle D., Krasuski J., et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biological Psychiatry 51 (2002) 659-667
68. Judd L.L., Akiskal H.S., Zeller P.J., Paulus M., Leon A.C., Maser J.D., et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Archives of General Psychiatry 57 (2000) 375-380
69. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. International Journal of Clinical Psychopharmacology 10 Suppl. 4 (1995) 25-35
70. Kasper S., Zivkov M., Roes K.C., and Pols A.G. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. European Neuropsychopharmacology 7 (1997) 115-124
71. Katon W.J. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biological Psychiatry 54 (2003) 216-226
72. Keitner G.I., Miller I.W., and Ryan C.E. Family functioning in severe depressive disorders. In: Grunhaus L., and Greden J.F. (Eds). Severe depressive disorders (1994), American Psychiatric Press, Washington, DC 89-110
73. Keitner G., Ninan P.T., Ryan C.E., Garlow S.T., Soloman D.A., Nemeroff C.B., et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult to treat unipolar non-psychotic major depression. Neuropsychopharmacology 30 Suppl. 1 (2005) 5175
74. Keller M.B., Lavori P.W., Mueller T.I., Endicott J., Coryell W., Hirschfeld R.M., et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Archives of General Psychiatry 49 (1992) 809-816
75. Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine 342 (2000) 1462-1470
76. Kennedy S.H., Andersen H.F., and Lam R.W. Efficacy of escitalopram in the treatment of major depression disorder compared with conventional serotonin reuptake inhibitors and venlafaxine XR: a metaanalysis. Journal of Psychiatry and Neuroscience 31 (2006) 122-131
77. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003) 3095-3105
78. Kienke A.S., and Rosenbaum J.F. Efficacy of venlafaxine in the treatment of severe depression. Depression and Anxiety 12 Suppl. 1 (2000) 50-54
79. Krishnan K.R.R. Monoamine oxidase inhibitors. In: Schatzberg A., and Nemeroff C.B. (Eds). Essentials of clinical psychopharmacology (2001), American Psychiatric Press, Washington, DC 43-53
80. Lecrubier Y. Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug and Safety 10 (1994) 292-300
81. Lecrubier Y., Pletan Y., Solles A., Tournoux A., and Magne V. Clinical efficacy of milnacipran: placebo-controlled trials. International Journal of Clinical Psychopharmacology 11 Suppl. 4 (1996) 29-33
82. Leinonen E., Skarstein J., Behnke K., Agren H., and Helsdingen J.T. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. International Journal of Clinical Psychopharmacology 14 (1999) 329-337
83. Lepine J.P., Goger J., Blashko C., Probst C., Moles M.F., Kosolowski J., et al. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. International Journal of Clinical Psychopharmacology 15 (2000) 263-271
84. Llorca P.M., Azorin J.M., Despiegel N., and Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. International Journal of Clinical Practice 59 (2005) 268-275
85. Lopez-Ibor J., Guelfi J.D., Pletan Y., Tournoux A., and Prost J.F. Milnacipran and selective serotonin reuptake inhibitors in major depression. International Journal of Clinical Psychopharmacology 11 Suppl. 4 (1996) 41-46
86. Macher J.P., Sichel J.P., Serre C., Von Frenckell R., Huck J.C., and Demarez J.P. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22 (1989) 77-82
87. Mallinckrodt C.H., Goldstein D.J., Detke M.J., Lu Y., Watkin J.G., and Tran P.V. Duloxetine: A new treatment for the emotional and physical symptoms of depression. Primitive Care Companion Journal of Clinical Psychiatry 5 (2003) 19-28
88. Marangell L.B., Rush A.J., George M.S., Sackeim H.A., Johnson C.R., Husain M.M., et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biological Psychiatry 51 (2002) 280-287
89. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., et al. Deep brain stimulation for treatment-resistant depression. Neuron 45 (2005) 651-660
90. McDonald W.M., Thompson T.R., McCall W.V., and Zorumxki C.F. Electroconvulsive therapy. In: Schatzberg A.F., and Nemeroff C.B. (Eds). Textbook of psychopharmacology. 3rd ed. (2004), American Psychiatric Publishing, Inc., Washington, DC 685-714
91. Merideth C.H., and Feighner J.P. The use of bupropion in hospitalized depressed patients. Journal of Clinical Psychiatry 44 (1983) 85-87
92. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134 (1979) 382-389
93. Montgomery S.A., and Lecrubier Y. Is severe depression a separate indication? Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology. European Neuropsychopharmacology 9 (1999) 259-264
94. Moon C.A., Laws D., Stott P.C., and Hayes G. Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice. Current Medical Research Opinion 12 (1990) 160-168
95. Moore N., Verdoux H., and Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Journal of Clinical Psychopharmacology 20 (2005) 131-137
96. Muller M.J., Himmerich H., Kienzle B., and Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). Journal of Affective Disorders 77 (2003) 255-260
97. Nelson J.C., Mazure C.M., Bowers Jr. M.B., and Jatlow P.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry 48 (1991) 303-307
98. Nelson J.C., Mazure C.M., Jatlow P.I., Bowers Jr. M.B., and Price L.H. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 55 (2004) 296-300
99. Nemeroff C.B. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy 14 (1994) 127-138
100. Nemeroff CB, Thase ME. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Journal of Psychiatric Research 2005, in press.
101. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., Detke M.J., Mallinckrodt C., Lu Y., et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacological Bulletin 36 (2002) 106-132
102. Nemeroff CB, Entsuah R, Willard LB, Demitrack MA, Thase ME. Venlafaxine and SSRIs: Comprehensive Pooled Analysis of Remission in Depression, New Clinical Drug Evaluation Unit. Boca Raton, FL, 2003.
103. Nemeroff C.B., Gharabawi G.M., Canuso C.M., Mahmoud R., Loescher A., Turkoz I., et al. Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial. Neuropsychopharmacology 29 (2004) S159
104. Nierenberg A.A. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations?. Journal of Clinical Psychiatry 55 Suppl. A (1994) 55-59
105. Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression (abstract): National Institute of Mental Health/NCDEU, 2003.
106. Ostroff R.B., and Nelson J.C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Journal of Clinical Psychiatry 60 (1999) 256-259
107. Ottevanger E.A. The efficacy of fluvoxamine in patients with severe depression. Progress in Neuropsychopharmacology and Biological Psychiatry 18 (1994) 731-740
108. Ottevanger E.A. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Encephale 21 (1995) 317-321
109. Pagnin D., de Queiroz V., Pini S., and Cassano G.B. Efficacy of ECT in depression: a meta-analytic review. Journal of ECT 20 (2004) 13-20
110. Pande A.C., and Sayler M.E. Severity of depression and response to fluoxetine. International Journal of Clinical Psychopharmacology 8 (1993) 243-245
111. Papakostas G.I., Petersen T.J., Nierenberg A.A., Murakami J.L., Alpert J.E., Rosenbaum J.F., et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Journal of Clinical Psychiatry 65 (2004) 217-221
112. Parker G., Brotchie H., and Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?. American Journal of Psychiatry 162 (2005) 796-798
113. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990;18:289-99.
114. Pitts W.M., Fann W.E., Halaris A.E., Dressler D.M., Sajadi C., Snyder S., et al. Bupropion in depression: a tri-center placebo-controlled study. Journal of Clinical Psychiatry 44 (1983) 95-100
115. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000b;157:1-45.
116. Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy. Depression and Anxiety 12 (2000) 118-123
117. Quitkin F.M. Depression with atypical features: diagnostic validity, prevalence, and treatment. Primitive Care Companion Journal of Clinical Psychiatry 4 (2002) 94-99
118. Reimherr F.W., Cunningham L.A., Batey S.R., Johnston J.A., and Ascher J.A. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clincal Therapy 20 (1998) 505-516
119. Roose S.P. Treatment of depression in patients with heart disease. Biological Psychiatry 54 (2003) 262-268
120. Roose S.P., Glassman A.H., Attia E., and Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 151 (1994) 1735-1759
121. Rush A.J., Koran L.M., Keller M.B., Markowitz J.C., Harrison W.M., Miceli R.J., et al. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Journal of Clinical Psychiatry 59 (1998) 589-597
122. Rush A.J., George M.S., Sackeim H.A., Marangell L.B., Husain M.M., Giller C., et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biological Psychiatry 47 (2000) 276-286
123. Rush A.J., Trivedi M., and Fava M. Depression, IV: STAR*D treatment trial for depression. American Journal of Psychiatry 160 (2003) 237
124. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354 (2006) 1231-1242
125. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. Jama 285 (2001) 1299-1307
126. Sackeim H.A., Rush A.J., George M.S., Marangell L.B., Husain M.M., Nahas Z., et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 25 (2001) 713-728
127. Saletu-Zyhlarz G.M., Anderer P., Arnold O., and Saletu B. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology 48 (2003) 194-208
128. Schatzberg A.F. Antidepressant effectiveness in severe depression and melancholia. Journal of Clinical Psychiatry 60 Suppl. 4 (1999) 14-21
129. Schatzberg A.F., and Cantillon M. Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients. European Neuropsychopharmacology 10 (2000) S225-S226
130. Schatzberg A.F., Kremer C., Rodrigues H.E., and Murphy Jr. G.M. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. American Journal of Geriatric Psychiatry 10 (2002) 541-550
131. Schlaepfer T.E., Kosel M., and Nemeroff C.B. Efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of affective disorders. Neuropsychopharmacology 28 (2003) 201-205
132. Segal Z., Vincent P., and Levitt A. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. Journal of Psychiatry and Neuroscience 27 (2002) 281-290
133. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 158 (2001) 131-134
134. Simon G.E. Social and economic burden of mood disorders. Biological Psychiatry 54 (2003) 208-215
135. Simon J.S., and Nemeroff C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. Journal of Clinical Psychiatry 66 (2005) 1216-1220
136. Simon JS, Sheehan DV, Thase ME, Owens MJ, Krulewicz S, Carpenter DJ. et al. Comparison of efficacy and tolerability of paroxetine CR versus venlafaxine XR [Abstract], Annual Meeting of the American Psychiatric Association. Atlanta, GA, 2005b.
137. Sonawalla S.B., and Fava M. Severe depression: is there a best approach?. CNS Drugs 15 (2001) 765-776
138. Stabl M., Kasas A., Blajev B., Bajetta G., Zochling R., Holsboer-Trachsler E., et al. A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression. Journal of Clinical Psychopharmacology 15 (1995) 41S-45S
139. Tani K., Takei N., Kawai M., Suzuki K., Sekine Y., Toyoda T., et al. Augmentation of milnacipran by risperidone in treatment for major depression. International Journal of Neuropsychopharmacology 7 (2004) 55-58
140. Thase M.E. Treatment of severe depression. Journal of Clinical Psychiatry 61 (2000) 17-25
141. Thase M.E., Frank E., Mallinger A.G., Hamer T., and Kupfer D.J. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. Journal of Clinical Psychiatry 53 (1992) 5-11
142. Thase M.E., Greenhouse J.B., Frank E., Reynolds III C.F., Pilkonis P.A., Hurley K., et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry 54 (1997) 1009-1015
143. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178 (2001) 234-241
144. Thase M.E., Wang Y., Richard N., Mitton M., Haight B., and Goodale E. Remission rates following therapy with bupropion or selective serotonin reuptake inhibitors. European Neuropsychopharmacology 13 Suppl. 4 (2003) S259
145. Thase M.E., Entsuah R., Ahmed S., Sloan D., and Nemeroff C.B. Venlafaxine vs SSRIs in depression: meta-analysis of all known RCTs [Abstract]. World Journal of Biological Psychiatry 6 (2005) 285
146. Trivedi M.H., Rush A.J., Crismon M.L., Kashner T.M., Toprac M.G., Carmody T.J., et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Archives of General Psychiatry 61 (2004) 669-680
147. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354 (2006) 1243-1252
148. Valuck R. Selective serotonin reuptake inhibitors: A class review. P& T 29 (2004) 234-243
149. Vitton O., Gendreau M., Gendreau J., Kranzler J., and Rao S.G. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology 19 Suppl. 1 (2004) S27-S35
150. Wheatley D.P., van Moffaert M., Timmerman L., and Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. Journal of Clinical Psychiatry 59 (1998) 306-312
151. Whooley M.A., and Browner W.S. Association between depressive symptoms and mortality in older women. Study of Osteoporotic Fractures Research Group. Archives of Internal Medicine 158 (1998) 2129-2135
152. Yoshida K., Takahashi H., Higuchi H., Kamata M., Ito K., Sato K., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. American Journal of Psychiatry 161 (2004) 1575-1580
153. Zajecka J.M. Treating depression to remission. Journal of Clinical Psychiatry 64 Suppl. 15 (2003) 7-12
154. Zajecka J.M., Jeffries H., and Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. Journal of Clinical Psychiatry 56 (1995) 338-343
155. Zanardi R., Franchini L., Serretti A., Perez J., and Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry 61 (2000) 26-29
156. Zarate Jr. C.A., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry 56 (2004) 54-60
157. Zimmerman M., Chelminski I., and Posternak M. A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. Journal of Nervous Mental Disorder 192 (2004) 595-601
158. Zohar J., Keegstra H., and Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Human Psychopharmacology 18 (2003) 113-119